TITLE:
Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

CONDITION:
Type 2 Diabetes Mellitus

INTERVENTION:
exenatide/insulin glargine

SUMMARY:

      This is a study with two treatment sequences and two treatment periods that will assess the
      safety and efficacy of exenatide treatment in patients with type 2 diabetes who have
      inadequate glycemic control using metformin or sulfonylurea and for whom insulin is the next
      appropriate step in diabetes treatment.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 30 Years to N/A
Criteria:

        Main Inclusion Criteria:

          -  Treated with a stable dose of metformin or sulfonylurea for at least 3 months prior
             to screening.

          -  HbA1c between 7.1% and 11.0%, inclusive.

          -  Insulin therapy should be the next appropriate step of diabetes treatment.

          -  Body Mass Index (BMI) >25 kg/m2 and <40 kg/m2.

        Main Exclusion Criteria:

          -  Patient previously in a study involving exenatide or glucagon-like peptide-1 analogs.

          -  Treated with insulin, thiazolidinediones, alpha-glucosidase inhibitors, or
             meglitinides within 3 months prior to screening.
      
